menu
    • menu
    [{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Incyte","highestDevelopmentStatusID":"2","companyTruncated":"Nimble Therapeutics \/ Incyte"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":1.1200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.1200000000000001,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Peptide","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ AbbVie Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Nimble Therapeutics

    Menu

    Nimble Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nimble Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Nimble Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peptide

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : $200.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            AbbVie Buys Roche Spinout Nimble Therapeutics for $200M

                            Details : AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : $200.0 million

                            December 13, 2024

                            Lead Product(s) : Peptide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : $200.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nimble Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Nimble Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Genentech

                            Deal Size : $1,120.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech

                            Details : Nimble will apply its platform against multiple targets, and Genentech and Roche will be responsible for preclinical and clinical development, and commercialization of any resulting products.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : $20.0 million

                            January 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Genentech

                            Deal Size : $1,120.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nimble Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Nimble Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nimble Therapeutics Delivers Lead Compounds for Two Programs Under Collaboration with Large Pharma Partner, Tr...

                            Details : Nimble has delivered lead compounds for four programs to its partners. This progress, across multiple targets and partners, validates the power of Nimble’s platform to optimize peptide therapeutics at unprecedented speed.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            December 13, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nimble Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Nimble Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nimble Therapeutics Announces Achievement of Development Milestones From Multiple Partnered Programs Connected...

                            Details : Nimble will receive payments for each milestone connected to the collaboration, and the company remains eligible for additional future downstream milestones attached to each program as development continues.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 17, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nimble Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Nimble Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Incyte Corporation

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Pept...

                            Details : Incyte has exclusive rights to develop and commercialize any peptides discovered under the collaboration and has an option to further expand the collaboration to include additional targets.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 14, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Incyte Corporation

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth